-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Pharmaceutical Stock Market] News on September 23, Fuxiang Pharmaceutical continued its recent strength, with a daily daily limit, and the stock price closed up 14.
26% to 22.
04 yuan in late trading, hitting a new high since August 2016
.
It is reported that the stock has risen by 112.
13% since the start of the rising market on July 29, and the market value has also reached the mark of 5 billion to 12 billion
.
The stock price and market value doubled within two months, and Fuxiang Pharmaceutical quickly attracted the attention of institutions
.
On September 5, the company announced that 64 institutions including Essence Securities and Caidao Asset Management investigated the company on September 2
.
From the survey content, the institution mainly paid attention to the situation of Lingfu Pharmaceutical Research Institute and the overall development strategy of Fuxiang Pharmaceutical.
Among them, in terms of development strategy, Fuxiang Pharmaceutical replied that the company has always adhered to the principle of "pharmaceutical intermediates— The "API-Preparation" vertical integration development strategy is driven by innovation and development
.
According to reports, in recent years, the company has continuously implemented development strategies through acquisitions, refinancing and other means
.
The specific measures mainly include: in 2017, through the acquisition of Fuxiang (Dalian) Pharmaceutical, it began to test the field of water preparations, and the products on sale are doxycycline tablets and argatroban injection; in 2019 and 2021, they successfully issued convertible bonds, Issue stocks to specific objects to raise funds for the construction of industrial chain extension projects; sign a strategic cooperation agreement with Jingdezhen Municipal Government in 2020 to build a 1,000-mu Fuxiang biomedical project; establish a joint venture with Shanghai Lingkai Pharmaceutical Technology Co.
, Ltd.
in 2021 Shanghai Lingfu Pharmaceutical Research Co.
, Ltd.
has accumulated experience for the company to deploy CDMO business
.
As the stock price skyrocketed in a short period of time, Fuxiang Pharmaceutical received a letter of concern from the Shenzhen Stock Exchange on September 16, requesting additional disclosure of the main business and specific business model of Shanghai Lingfu, as well as the ownership of intellectual property rights of Shanghai Lingfu’s products under development.
Whether the relevant arrangements are in line with industry practices; analyze the reasons why the company's stock price rises significantly deviated from the broader market, explain whether the company's fundamentals have undergone major changes, and provide adequate risk warnings for the company's recent large stock price increases
.
In this regard, Fuxiang Pharmaceutical responded to the letter of concern, saying that Shanghai Lingfu is in the initial stage.
Although there are some orders, it has not yet formed official sales, and the scale of revenue and market share have not yet appeared.
In addition, Shanghai Lingfu's performance continues to be The ability to grow is affected by objective circumstances such as changes in the market environment, the exertion of shareholders' integration advantages, and the construction of its own platform
.
In addition, for the doubling of the stock price, Fuxiang Pharmaceutical explained that there are three main reasons for the continuous rise of the company's stock price since the end of July: First, it established a joint venture with Lingkai Pharmaceutical to establish Shanghai Lingfu Research Co.
, Ltd.
, which helped the company to deploy its CDMO business.
, to enhance the overall competitiveness of the company in the future; second, the company previously planned to repurchase the company's shares at 18 yuan per share, and the actual controller and related parties plan to increase their holdings by 50 to 100 million yuan; third, the pharmaceutical sector has recently been differentiated, with low valuations The company was excavated
.
According to public information, Fuxiang Pharmaceutical is a pharmaceutical company engaged in the research and development, production, sales and service of chemical drugs
.
Its main business is the research and development, production and sales of high-end antibiotic APIs and their intermediates, as well as antiviral drug intermediates
.
It is worth noting that the 2021 interim report shows that the gross profit margin of Fuxiang Pharmaceutical's main business is in a year-on-year decline
.
Among them, the main income was 776 million yuan, a year-on-year decrease of 4.
97%; the net profit attributable to the parent was 152 million yuan, a year-on-year decrease of 30.
51%; the non-net profit was 137 million yuan, a year-on-year decrease of 34.
13%; the debt ratio was 28.
97%, and the investment income was -4.
3471 million RMB 2.
4592 million in financial expenses and 35.
23% gross profit margin
.
26% to 22.
04 yuan in late trading, hitting a new high since August 2016
.
It is reported that the stock has risen by 112.
13% since the start of the rising market on July 29, and the market value has also reached the mark of 5 billion to 12 billion
.
The stock price and market value doubled within two months, and Fuxiang Pharmaceutical quickly attracted the attention of institutions
.
On September 5, the company announced that 64 institutions including Essence Securities and Caidao Asset Management investigated the company on September 2
.
From the survey content, the institution mainly paid attention to the situation of Lingfu Pharmaceutical Research Institute and the overall development strategy of Fuxiang Pharmaceutical.
Among them, in terms of development strategy, Fuxiang Pharmaceutical replied that the company has always adhered to the principle of "pharmaceutical intermediates— The "API-Preparation" vertical integration development strategy is driven by innovation and development
.
According to reports, in recent years, the company has continuously implemented development strategies through acquisitions, refinancing and other means
.
The specific measures mainly include: in 2017, through the acquisition of Fuxiang (Dalian) Pharmaceutical, it began to test the field of water preparations, and the products on sale are doxycycline tablets and argatroban injection; in 2019 and 2021, they successfully issued convertible bonds, Issue stocks to specific objects to raise funds for the construction of industrial chain extension projects; sign a strategic cooperation agreement with Jingdezhen Municipal Government in 2020 to build a 1,000-mu Fuxiang biomedical project; establish a joint venture with Shanghai Lingkai Pharmaceutical Technology Co.
, Ltd.
in 2021 Shanghai Lingfu Pharmaceutical Research Co.
, Ltd.
has accumulated experience for the company to deploy CDMO business
.
As the stock price skyrocketed in a short period of time, Fuxiang Pharmaceutical received a letter of concern from the Shenzhen Stock Exchange on September 16, requesting additional disclosure of the main business and specific business model of Shanghai Lingfu, as well as the ownership of intellectual property rights of Shanghai Lingfu’s products under development.
Whether the relevant arrangements are in line with industry practices; analyze the reasons why the company's stock price rises significantly deviated from the broader market, explain whether the company's fundamentals have undergone major changes, and provide adequate risk warnings for the company's recent large stock price increases
.
In this regard, Fuxiang Pharmaceutical responded to the letter of concern, saying that Shanghai Lingfu is in the initial stage.
Although there are some orders, it has not yet formed official sales, and the scale of revenue and market share have not yet appeared.
In addition, Shanghai Lingfu's performance continues to be The ability to grow is affected by objective circumstances such as changes in the market environment, the exertion of shareholders' integration advantages, and the construction of its own platform
.
In addition, for the doubling of the stock price, Fuxiang Pharmaceutical explained that there are three main reasons for the continuous rise of the company's stock price since the end of July: First, it established a joint venture with Lingkai Pharmaceutical to establish Shanghai Lingfu Research Co.
, Ltd.
, which helped the company to deploy its CDMO business.
, to enhance the overall competitiveness of the company in the future; second, the company previously planned to repurchase the company's shares at 18 yuan per share, and the actual controller and related parties plan to increase their holdings by 50 to 100 million yuan; third, the pharmaceutical sector has recently been differentiated, with low valuations The company was excavated
.
According to public information, Fuxiang Pharmaceutical is a pharmaceutical company engaged in the research and development, production, sales and service of chemical drugs
.
Its main business is the research and development, production and sales of high-end antibiotic APIs and their intermediates, as well as antiviral drug intermediates
.
It is worth noting that the 2021 interim report shows that the gross profit margin of Fuxiang Pharmaceutical's main business is in a year-on-year decline
.
Among them, the main income was 776 million yuan, a year-on-year decrease of 4.
97%; the net profit attributable to the parent was 152 million yuan, a year-on-year decrease of 30.
51%; the non-net profit was 137 million yuan, a year-on-year decrease of 34.
13%; the debt ratio was 28.
97%, and the investment income was -4.
3471 million RMB 2.
4592 million in financial expenses and 35.
23% gross profit margin
.
